Clinical Trial Update: Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients [Phase 3]

View source ↗

Summary

This document provides an update on the Phase 3 efficacy and safety study of PEX168 as monotherapy in adults with type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PEX168 (PEX168)

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: UNKNOWN